Dr. Israel Lowy is the vice president of Clinical Sciences and the head of Translational Science and of Oncology at Regeneron Pharmaceuticals, where he has focused on developing novel immunotherapies, antibody-drug conjugates, and treatments that target tumor blood vessels. Dr. Lowy is a member of CRI’s Cancer Immunotherapy Consortium (CIC) Steering Committee.
I believe this area is poised for a renaissance to identify new, precise antibody therapeutic candidates.
Let's spread the word about Immunotherapy! Click to share this page with your community.